

Michael W Fried

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11503401/publications.pdf>

Version: 2024-02-01

152
papers

22,211
citations

22099

59
h-index

8370

147
g-index

156
all docs

156
docs citations

156
times ranked

13429
citing authors

#	ARTICLE	IF	CITATIONS
1	Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection. <i>New England Journal of Medicine</i> , 2002, 347, 975-982.	13.9	6,268
2	Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2005, 352, 2682-2695.	13.9	1,465
3	Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis. <i>New England Journal of Medicine</i> , 2014, 370, 1879-1888.	13.9	1,080
4	Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. <i>Gastroenterology</i> , 2015, 149, 649-659.	0.6	725
5	Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection. <i>New England Journal of Medicine</i> , 2011, 365, 1014-1024.	13.9	716
6	Hepatic Failure and Lactic Acidosis Due to Fialuridine (FIAU), an Investigational Nucleoside Analogue for Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 1995, 333, 1099-1105.	13.9	593
7	Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection. <i>Annals of Internal Medicine</i> , 2017, 166, 637.	2.0	540
8	Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. <i>Journal of Hepatology</i> , 2005, 43, 425-433.	1.8	484
9	Side effects of therapy of hepatitis C and their management. <i>Hepatology</i> , 2002, 36, S237-S244.	3.6	470
10	Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients With Hepatitis C Genotype 1. <i>Gastroenterology</i> , 2006, 131, 470-477.	0.6	453
11	Side effects of therapy of hepatitis C and their management. <i>Hepatology</i> , 2002, 36, s237-s244.	3.6	445
12	Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2014, 384, 403-413.	6.3	431
13	Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). <i>Journal of Hepatology</i> , 2002, 37, 500-506.	1.8	388
14	Efficacy and safety of pegylated (40-kd) interferon α -2a compared with interferon α -2a in noncirrhotic patients with chronic hepatitis C. <i>Hepatology</i> , 2001, 33, 433-438.	3.6	317
15	Management of hepatitis C in the hemophilia patient. <i>American Journal of Medicine</i> , 1999, 107, 85-89.	0.6	293
16	A pilot study of ribavirin therapy for chronic hepatitis C. <i>Hepatology</i> , 1992, 16, 649-654.	3.6	284
17	Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. <i>Liver International</i> , 2016, 36, 807-816.	1.9	270
18	Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study. <i>Hepatology</i> , 2013, 58, 1918-1929.	3.6	255

#	ARTICLE	IF	CITATIONS
19	Side effects of therapy for chronic hepatitis C. <i>Gastroenterology</i> , 2003, 124, 1711-1719.	0.6	245
20	Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. <i>Hepatology</i> , 2007, 46, 1548-1563.	3.6	242
21	Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial. <i>Gastroenterology</i> , 2014, 146, 430-441.e6.	0.6	217
22	HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. <i>Hepatology</i> , 2008, 47, 428-434.	3.6	211
23	Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. <i>Gastroenterology</i> , 2016, 151, 1131-1140.e5.	0.6	199
24	Hepatitis B Virus-Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. <i>Gastroenterology</i> , 2016, 150, 684-695.e5.	0.6	178
25	Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. <i>Hepatology</i> , 2017, 66, 389-397.	3.6	172
26	Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia and Decrease the Need for Ribavirin Dose Reduction. <i>Gastroenterology</i> , 2010, 139, 1181-1189.e2.	0.6	171
27	Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. <i>Gastroenterology</i> , 2016, 150, 419-429.	0.6	166
28	Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. <i>Journal of Hepatology</i> , 2001, 35, 749-755.	1.8	161
29	Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2011, 55, 69-75.	1.8	160
30	Pharmacokinetics and Metabolic Profile of Free, Conjugated, and Total Silymarin Flavonolignans in Human Plasma after Oral Administration of Milk Thistle Extract. <i>Drug Metabolism and Disposition</i> , 2008, 36, 65-72.	1.7	155
31	Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study. <i>Hepatology</i> , 2017, 66, 1090-1101.	3.6	149
32	Barriers to hepatitis C treatment. <i>Liver International</i> , 2012, 32, 151-156.	1.9	141
33	Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. <i>Hepatology</i> , 2011, 53, 32-41.	3.6	140
34	Effect of Silymarin (Milk Thistle) on Liver Disease in Patients With Chronic Hepatitis C Unsuccessfully Treated With Interferon Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 274.	3.8	134
35	Hepatitis C virus treatment in the real world: optimising treatment and access to therapies: Table 1. <i>Cut</i> , 2015, 64, 1824-1833.	6.1	128
36	Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis C. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 434-449.	1.0	125

#	ARTICLE	IF	CITATIONS
37	Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. <i>Hepatology</i> , 2018, 67, 1253-1260.	3.6	119
38	Current therapy for hepatitis C: pegylated interferon and ribavirin. <i>Clinics in Liver Disease</i> , 2003, 7, 149-161.	1.0	105
39	R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. <i>Hepatology</i> , 2008, 48, 385-397.	3.6	101
40	Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. <i>Gut</i> , 2015, 64, 948-956.	6.1	101
41	Defective Hepatic Response to Interferon and Activation of Suppressor of Cytokine Signaling 3 in Chronic Hepatitis C. <i>Gastroenterology</i> , 2007, 132, 733-744.	0.6	100
42	Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. <i>Liver Transplantation</i> , 2016, 22, 24-33.	1.3	100
43	Quantitation of pretreatment serum interferon- λ 3-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. <i>Hepatology</i> , 2011, 53, 14-22.	3.6	94
44	Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and Hepatitis B Virus Genotype. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 183-192.	2.4	90
45	Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation?. <i>Liver Transplantation</i> , 1998, 4, 128-132.	1.9	89
46	A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care. <i>Hepatology</i> , 2013, 57, 1325-1332.	3.6	89
47	Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGET. <i>Journal of Hepatology</i> , 2015, 62, 286-293.	1.8	86
48	Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis. <i>Digestive Diseases and Sciences</i> , 1993, 38, 631-636.	1.1	85
49	DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. <i>Journal of Hepatology</i> , 2020, 73, 540-548.	1.8	85
50	Social Stigmatization and Hepatitis C Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 220-224.	1.1	80
51	Efficacy and Safety of Two-Dose Regimens of Peginterferon Alpha-2a Compared with Interferon Alpha-2a in Chronic Hepatitis C: A Multicenter, Randomized Controlled Trial. <i>American Journal of Gastroenterology</i> , 2004, 99, 1298-1305.	0.2	75
52	Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: Randomized study of higher doses of peginterferon λ 3-2a and ribavirin. <i>Hepatology</i> , 2008, 48, 1033-1043.	3.6	75
53	The Pharmacokinetics of Silymarin Is Altered in Patients with Hepatitis C Virus and Nonalcoholic Fatty Liver Disease and Correlates with Plasma Caspase-3/7 Activity. <i>Drug Metabolism and Disposition</i> , 2008, 36, 1909-1916.	1.7	74
54	Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. <i>Gut</i> , 2017, 66, 1844-1852.	6.1	69

#	ARTICLE	IF	CITATIONS
55	American Gastroenterological Association Institute Clinical Practice Update—Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. <i>Gastroenterology</i> , 2017, 152, 1578-1587.	0.6	69
56	Treatment of Chronic Hepatitis C Infection with Peginterferons Plus Ribavirin. <i>Seminars in Liver Disease</i> , 2004, 24, 47-54.	1.8	68
57	Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C. <i>Liver Transplantation</i> , 2005, 11, 1235-1241.	1.3	66
58	A Randomized Controlled Trial of an Integrated Care Intervention to Increase Eligibility for Chronic Hepatitis C Treatment. <i>American Journal of Gastroenterology</i> , 2011, 106, 1777-1786.	0.2	63
59	Hepatitis C in adults and adolescents with hemophilia: A randomized, controlled trial of interferon alfa-2b and ribavirin. <i>Hepatology</i> , 2002, 36, 967-972.	3.6	62
60	Prospective Analysis of Depression During Peginterferon and Ribavirin Therapy of Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2009, 104, 2949-295.	0.2	57
61	Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial. <i>PLoS ONE</i> , 2019, 14, e0221683.	1.1	57
62	Early Predictors of Anemia in Patients With Hepatitis C Genotype 1 Treated With Peginterferon Alfa-2a (40KD) Plus Ribavirin. <i>American Journal of Gastroenterology</i> , 2008, 103, 1981-1988.	0.2	53
63	Assessing the Validity of Self-Reported Medication Adherence in Hepatitis C Treatment. <i>Annals of Pharmacotherapy</i> , 2007, 41, 1116-1123.	0.9	52
64	A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: pretreatment stratification by viral burden and genotype. <i>American Journal of Gastroenterology</i> , 2000, 95, 3225-3229.	0.2	51
65	Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon α for chronic hepatitis C. <i>Journal of Hepatology</i> , 2003, 39, 106-111.	1.8	51
66	Maximizing Opportunities and Avoiding Mistakes in Triple Therapy for Hepatitis C Virus. <i>Gastroenterology</i> , 2012, 142, 1314-1323.e1.	0.6	50
67	Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 247-255.	0.6	48
68	High Deferral Rates and Poorer Treatment Outcomes for HCV Patients with Psychiatric and Substance Use Comorbidities. <i>Digestive Diseases and Sciences</i> , 2007, 52, 3251-3258.	1.1	47
69	Differences in the Disposition of Silymarin between Patients with Nonalcoholic Fatty Liver Disease and Chronic Hepatitis C. <i>Drug Metabolism and Disposition</i> , 2011, 39, 2182-2190.	1.7	47
70	Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1073-1082.	0.8	46
71	Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 776-783.	2.9	45
72	Randomized Study of Asunaprevir plus Pegylated Interferon α and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2013, 18, 885-893.	0.6	44

#	ARTICLE	IF	CITATIONS
73	A pilot study of 2â€™,3â€™-dideoxyinosine for the treatment of chronic hepatitis B. <i>Hepatology</i> , 1992, 16, 861-864.	3.6	41
74	Therapy of chronic hepatitis B with a 6-month course of ribavirin. <i>Journal of Hepatology</i> , 1994, 21, 145-150.	1.8	38
75	Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. <i>Journal of Hepatology</i> , 2019, 71, 486-497.	1.8	37
76	Time to Rethink Antiviral Treatment for Hepatitis C in Patients with Coexisting Mental Health/Substance Abuse Issues. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1469-1474.	1.1	33
77	Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. <i>Gastroenterology</i> , 2019, 157, 1506-1517.e1.	0.6	32
78	Hepatitis C Virus (HCV) NS3 Sequence Diversity and Antiviral Resistance-Associated Variant Frequency in HCV/HIV Coinfection. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6079-6092.	1.4	29
79	Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2541-2551.e2.	2.4	28
80	Internal biliary stenting in orthotopic liver transplantation. <i>Liver Transplantation</i> , 2000, 6, 356-361.	1.3	24
81	Chronic hepatitis C and antiviral treatment regimens: Where can psychology contribute?. <i>Journal of Consulting and Clinical Psychology</i> , 2013, 81, 361-374.	1.6	24
82	A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C Infection. <i>Hepatology</i> , 2020, 71, 1894-1909.	3.6	24
83	THERAPY OF CHRONIC VIRAL HEPATITIS. <i>Medical Clinics of North America</i> , 1996, 80, 957-972.	1.1	23
84	A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. <i>PLoS ONE</i> , 2018, 13, e0196908.	1.1	23
85	Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. <i>Hepatology</i> , 2021, 73, 2124-2140.	3.6	23
86	Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C. <i>Digestive Diseases and Sciences</i> , 2003, 48, 140-145.	1.1	21
87	Guidelines for stopping therapy in chronic hepatitis C. <i>Current Gastroenterology Reports</i> , 2004, 6, 17-21.	1.1	21
88	Hepatitis C Virus: A Critical Appraisal of Approaches to Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 397-414.	2.4	20
89	Unexpected Maintenance of Hepatitis C Viral Diversity following Liver Transplantation. <i>Journal of Virology</i> , 2012, 86, 8432-8439.	1.5	20
90	Publicâ€“Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting Antivirals. <i>Gastroenterology</i> , 2017, 153, 626-631.	0.6	20

#	ARTICLE	IF	CITATIONS
91	Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1811-1819.e4.	2.4	20
92	Hemophilic Siblings With Chronic Hepatitis C: Familial Aggregation of Spontaneous and Treatment-Related Viral Clearance. <i>Gastroenterology</i> , 2006, 131, 757-764.	0.6	19
93	High relapse rate seen at week 72 for patients treated with R1626 combination therapy. <i>Hepatology</i> , 2008, 48, 1349-1350.	3.6	19
94	Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C. <i>Clinical Trials</i> , 2012, 9, 102-112.	0.7	19
95	An Efficient, Large-Scale Survey of Hepatitis C Viremia in the Democratic Republic of the Congo Using Dried Blood Spots. <i>Clinical Infectious Diseases</i> , 2018, 66, 254-260.	2.9	19
96	Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. <i>Scientific Reports</i> , 2018, 8, 3199.	1.6	18
97	Social support and clinical outcomes during antiviral therapy for chronic hepatitis C. <i>Journal of Psychosomatic Research</i> , 2011, 71, 349-356.	1.2	17
98	Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019, 26, 856-865.	1.0	17
99	Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation. <i>Hepatology</i> , 2020, 72, 1819-1837.	3.6	17
100	Optimizing Treatment Regimens in Hepatitis C. <i>Clinics in Liver Disease</i> , 2006, 10, 835-850.	1.0	16
101	Persistent Portosystemic Shunts After Liver Transplantation Causing Episodic Hepatic Encephalopathy. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1794-1798.	1.1	16
102	Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals. <i>Journal of General Internal Medicine</i> , 2020, 35, 1011-1020.	1.3	16
103	Elevated <sc>AST</sc> to <sc>platelet ratio index is associated with increased all-cause mortality among <sc>HIV</sc>-infected adults in Zambia. <i>Liver International</i> , 2015, 35, 1886-1892.	1.9	15
104	Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopenia and hypoalbuminaemia. <i>Liver International</i> , 2015, 35, 2358-2362.	1.9	15
105	Characteristics of US-Born Versus Foreign-Born Americans of African Descent With Chronic Hepatitis B. <i>American Journal of Epidemiology</i> , 2017, 186, 356-366.	1.6	15
106	Tangible Resources for Preparing Patients for Antiviral Therapy for Chronic Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1439-1444.	1.1	14
107	Daclatasvir and sofosbuvir treatment of decompensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real-world cohort. <i>Hepatology Communications</i> , 2018, 2, 354-363.	2.0	14
108	Diagnostic testing for hepatitis C: practical considerations. <i>American Journal of Medicine</i> , 1999, 107, 31-35.	0.6	13

#	ARTICLE	IF	CITATIONS
109	Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. <i>Contemporary Clinical Trials</i> , 2017, 57, 58-68.	0.8	13
110	ADVANCES IN THERAPY FOR CHRONIC HEPATITIS C. <i>Clinics in Liver Disease</i> , 2001, 5, 1009-1023.	1.0	12
111	A real-world observational cohort of patients with primary biliary cholangitis: TARGET primary biliary cholangitis study design and rationale. <i>Hepatology Communications</i> , 2018, 2, 484-491.	2.0	12
112	Hepatitis C and Alcohol: Fundamental and Translational Research Directions. <i>Alcoholism: Clinical and Experimental Research</i> , 2003, 27, 726-731.	1.4	11
113	Nitazoxanide: Beyond Parasites Toward a Novel Agent for Hepatitis C. <i>Gastroenterology</i> , 2009, 136, 760-763.	0.6	11
114	The role of triple therapy in HCV genotype 1-experienced patients. <i>Liver International</i> , 2011, 31, 58-61.	1.9	11
115	Deep Sequencing Analysis of HCV NS3 Resistance-Associated Variants and Mutation Linkage in Liver Transplant Recipients. <i>PLoS ONE</i> , 2013, 8, e69698.	1.1	11
116	Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis – A pooled analysis. <i>Journal of Hepatology</i> , 2017, 67, 700-707.	1.8	11
117	What's Important to the Patient? Informational Needs of Patients Making Decisions About Hepatitis C Treatment. <i>Patient</i> , 2017, 10, 335-344.	1.1	11
118	Patient-reported outcomes in a large North American cohort living with chronic hepatitis B virus: a cross-sectional analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 457-468.	1.9	11
119	Precore and Basal Core Promoter Hepatitis B Virus (HBV) Variants Are Present From a Young Age and Differ Across HBV Genotypes. <i>Hepatology</i> , 2021, 73, 1637-1651.	3.6	11
120	Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. <i>Liver International</i> , 2021, 41, 692-704.	1.9	11
121	CLINICAL APPLICATION OF HEPATITIS C VIRUS GENOTYPING AND QUANTITATION. <i>Clinics in Liver Disease</i> , 1997, 1, 631-646.	1.0	10
122	Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis. <i>Hepatology Communications</i> , 2019, 3, 1388-1399.	2.0	9
123	Sustained Virologic Response Rates With Telaprevir-Based Therapy in Treatment-Naive Patients Evaluated by Race or Ethnicity. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 336-344.	1.1	7
124	The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2018, 72, 73-85.	0.8	7
125	“œ If I Get Cured, My Whole Quality of Life Will Change” Patients’ Anticipated and Actualized Benefits Following Cure from Chronic Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2022, 67, 100-120.	1.1	7
126	A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. <i>Hepatology</i> , 2021, 74, 2952-2964.	3.6	7

#	ARTICLE	IF	CITATIONS
127	Changes in serum hepatitis B surface and e antigen, interferon-inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B. <i>Hepatology</i> , 2022, 76, 775-787.	3.6	7
128	Hepatitis C Infection With Normal Liver Chemistry Tests. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 503-505.	2.4	6
129	Hepatitis C viral infection in patients with hemophilia and hemolytic disorders. <i>Clinical Liver Disease</i> , 2012, 1, 95-97.	1.0	6
130	Treatment options of patients with chronic hepatitis C who have failed prior therapy. <i>Clinical Liver Disease</i> , 2016, 7, 40-44.	1.0	6
131	Hepatitis C: Current options for nonresponders to peginterferon and ribavirin. <i>Current Gastroenterology Reports</i> , 2008, 10, 53-59.	1.1	5
132	Prevalence and Impact of Hepatitis E Virus Infection Among Persons With Chronic Hepatitis B Living in the US and Canada. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz175.	0.4	5
133	Clinical significance of quantitative e antigen in a cohort of hepatitis B virus-infected children and adults in North America. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1042-1056.	1.0	5
134	Viral factors affecting the outcome of therapy for chronic hepatitis C. <i>Reviews in Gastroenterological Disorders</i> , 2004, 4 Suppl 1, S8-S13.	0.6	5
135	Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy. <i>Hepatitis Research and Treatment</i> , 2012, 2012, 1-21.	2.0	4
136	Hepatitis C Virus Outbreaks in Hemodialysis Centers: A Continuing Problem. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 140-142.	1.0	4
137	HCV Council "critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. <i>Liver International</i> , 2016, 36, 488-502.	1.9	4
138	High <sc>MIG</sc> (<sc>CXCL</sc>9) plasma levels favours response to peginterferon and ribavirin in <sc>HCV</sc>-infected patients regardless of <sc>DPP</sc>4 activity. <i>Liver International</i> , 2016, 36, 344-352.	1.9	4
139	Novel patient-reported outcomes (PROs) used in a pilot and feasibility study of a Cognitive Behavioral Coping Skills (CBCS) group intervention for patients with chronic hepatitis C. <i>Pilot and Feasibility Studies</i> , 2018, 4, 92.	0.5	4
140	Chronic hepatitis B virus monoinfection at a university hospital in Zambia. <i>World Journal of Hepatology</i> , 2018, 10, 622-628.	0.8	4
141	Development and pilot-testing of a cognitive behavioral coping skills group intervention for patients with chronic hepatitis C. <i>Contemporary Clinical Trials Communications</i> , 2017, 6, 85-96.	0.5	3
142	Controversies in hepatitis C therapy: Reactivation of hepatitis B virus. <i>Clinical Liver Disease</i> , 2017, 10, 87-92.	1.0	2
143	HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 259-261.	2.4	2
144	Genome-wide capture sequencing to detect hepatitis C virus at the end of antiviral therapy. <i>BMC Infectious Diseases</i> , 2020, 20, 632.	1.3	2

#	ARTICLE	IF	CITATIONS
145	Parsing the guidelines on guidelines: Balancing sensibility and conflict of interest. Hepatology, 2018, 68, 798-800.	3.6	1
146	Liver disease symptoms are associated with higher risk of adverse clinical outcomes: A longitudinal study of North American adults with chronic Hepatitis B. GastroHep, 2021, 3, 196-208.	0.3	1
147	Linkage of resistance-associated substitutions in GT1 sofosbuvir+ NS5A inhibitor failures treated with glecaprevir/pibrentasvir. Journal of Hepatology, 2021, 75, 820-828.	1.8	1
148	Response-guided therapy for acute hepatitis C: applying concepts from chronic treatment. Liver International, 2011, 31, 903-904.	1.9	0
149	Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfecting patients (ANRS-ACO13 HEPAVIH)". Journal of Hepatology, 2020, 72, 592-593.	1.8	0
150	Reply to: "HCV treatment in cirrhotic patients: Should we use a different approach for patients awaiting a liver transplant?". Journal of Hepatology, 2020, 73, 985-986.	1.8	0
151	Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study. Clinical Gastroenterology and Hepatology, 2022, , .	2.4	0
152	HCV Genotype 1: How are you Managing the Non-Responders and Relapsers? A North American Perspective. , 0, , 38-42.		0